EPKINLY Approved By U.S. FDA As The First And Only Bispecific Antibody To Treat Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA has approved AbbVie's EPKINLY (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). EPKINLY is being co-developed by AbbVie and Genmab as part of their oncology collaboration.
May 19, 2023 | 4:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's EPKINLY has been approved by the FDA as the first T-cell engaging bispecific antibody for treating relapsed or refractory DLBCL patients.
The FDA approval of EPKINLY is a significant milestone for AbbVie, as it marks the first and only T-cell engaging bispecific antibody for treating relapsed or refractory DLBCL patients. This approval expands AbbVie's oncology portfolio and could potentially lead to increased revenues and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100